miércoles, 1 de julio de 2015

Approved Risk Evaluation and Mitigation Strategies (REMS)

Approved Risk Evaluation and Mitigation Strategies (REMS)





REMS@FDA has been updated with the following new or updated information.
  1. Product-specific information for a recently approved ER/LA opioid analgesic, Hysingla ER (hydrocodone bitartrate extended-release) tablets
  2. Newly approved intermediate strengths of fentanyl transdermal systems
  3. Revised titration information for Dolophine (methadone HCl tablets).

No hay comentarios:

Publicar un comentario